Equities research analysts expect Can-Fite Biopharma Ltd (NASDAQ:CANF) to report earnings of ($0.58) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Can-Fite Biopharma’s earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.78). The firm is expected to issue its next quarterly earnings results on Friday, November 29th.
According to Zacks, analysts expect that Can-Fite Biopharma will report full year earnings of ($4.70) per share for the current fiscal year. For the next year, analysts forecast that the company will post earnings of ($1.03) per share, with EPS estimates ranging from ($1.74) to ($0.32). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Can-Fite Biopharma.
Can-Fite Biopharma (NASDAQ:CANF) last issued its earnings results on Friday, August 30th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.40). The company had revenue of $0.39 million during the quarter.
About Can-Fite Biopharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.
Further Reading: Different Types of Derivatives
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.